{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T20:34:49Z","timestamp":1791232489673,"version":"4.1.0"},"reference-count":32,"publisher":"Wiley","issue":"11","license":[{"start":{"date-parts":[[2008,10,21]],"date-time":"2008-10-21T00:00:00Z","timestamp":1224547200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Eur J Clin Investigation"],"published-print":{"date-parts":[[2008,11]]},"abstract":"<jats:title>ABSTRACT<\/jats:title><jats:p><jats:bold>Background\u2002<\/jats:bold> Systemic mastocytosis (SM) is a mast cell neoplasm in which neoplastic cells usually display the D816V\u2010mutated variant of <jats:italic>KIT<\/jats:italic>. Cladribine (2CdA) and dasatinib are two drugs that counteract the <jats:italic>in\u00a0vitro<\/jats:italic> growth of neoplastic mast cells in SM. However, only little is known about the <jats:italic>in\u00a0vivo<\/jats:italic> effects of these drugs in SM.<\/jats:p><jats:p><jats:bold>Patient and methods\u2002<\/jats:bold> We report on a patient with highly aggressive interferon\u2010alpha\u2010resistant SM who was treated with 2CdA and dasatinib. <jats:italic>In\u00a0vitro<\/jats:italic> pretesting revealed a response of neoplastic mast cells to both compounds with reasonable IC<jats:sub>50<\/jats:sub> values.<\/jats:p><jats:p><jats:bold>Results\u2002<\/jats:bold> The patient was treated with six cycles of 2CdA (0\u00b713\u00a0mg\u00a0kg<jats:sup>\u22121<\/jats:sup> intravenously daily on 5 consecutive days). Despite a short\u2010lived major clinical response and a decrease in serum tryptase, the patient progressed to mast cell leukaemia after the sixth cycle of 2CdA. The patient then received two further courses of 2CdA followed by treatment with dasatinib (100\u00a0mg per\u00a0os daily). However, no major response was obtained and the patient died from disease progression after 2\u00a0months.<\/jats:p><jats:p><jats:bold>Conclusions\u2002<\/jats:bold> In a patient with rapidly progressing aggressive\u00a0SM, neither 2CdA nor dasatinib produced a long\u2010lasting response <jats:italic>in\u00a0vivo<\/jats:italic>, despite encouraging <jats:italic>in\u00a0vitro<\/jats:italic> results. For such patients, alternative treatment strategies have to be developed.<\/jats:p>","DOI":"10.1111\/j.1365-2362.2008.02036.x","type":"journal-article","created":{"date-parts":[[2010,6,24]],"date-time":"2010-06-24T15:19:33Z","timestamp":1277392773000},"page":"869-873","source":"Crossref","is-referenced-by-count":47,"title":["Treatment responses to cladribine and dasatinib in rapidly progressing aggressive mastocytosis"],"prefix":"10.1111","volume":"38","author":[{"given":"K. J.","family":"Aichberger","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"W. R.","family":"Sperr","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K. V.","family":"Gleixner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Kretschmer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"Valent","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2008,10,21]]},"reference":[{"key":"e_1_2_6_2_2","doi-asserted-by":"publisher","DOI":"10.1111\/1523-1747.ep12468882"},{"key":"e_1_2_6_3_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2141.2003.04575.x"},{"key":"e_1_2_6_4_2","doi-asserted-by":"publisher","DOI":"10.1146\/annurev.med.55.091902.103822"},{"key":"e_1_2_6_5_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00277-002-0575-z"},{"key":"e_1_2_6_6_2","doi-asserted-by":"publisher","DOI":"10.1159\/000101711"},{"key":"e_1_2_6_7_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2362.2007.01807.x"},{"key":"e_1_2_6_8_2","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.92.23.10560"},{"key":"e_1_2_6_9_2","doi-asserted-by":"publisher","DOI":"10.1038\/ng0396-312"},{"key":"e_1_2_6_10_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2141.2001.02783.x"},{"key":"e_1_2_6_11_2","doi-asserted-by":"publisher","DOI":"10.1159\/000048179"},{"key":"e_1_2_6_12_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0301-472X(99)00145-9"},{"key":"e_1_2_6_13_2","doi-asserted-by":"publisher","DOI":"10.1172\/JCI116761"},{"key":"e_1_2_6_14_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.2007.06619.x"},{"key":"e_1_2_6_15_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.0960-135X.2004.01369.x"},{"key":"e_1_2_6_16_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.beha.2005.07.010"},{"key":"e_1_2_6_17_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.iac.2006.05.009"},{"key":"e_1_2_6_18_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2004-12-4617"},{"key":"e_1_2_6_19_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2005-04-1568"},{"key":"e_1_2_6_20_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.leu.2403887"},{"key":"e_1_2_6_21_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2005-07-3022"},{"key":"e_1_2_6_22_2","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-05-2050"},{"key":"e_1_2_6_23_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2005-10-3969"},{"key":"e_1_2_6_24_2","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.11339"},{"key":"e_1_2_6_25_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199202273260907"},{"key":"e_1_2_6_26_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0145-2126(03)00259-5"},{"key":"e_1_2_6_27_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2003-05-1699"},{"key":"e_1_2_6_28_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM200101253440415"},{"key":"e_1_2_6_29_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0145-2126(02)00168-6"},{"key":"e_1_2_6_30_2","doi-asserted-by":"crossref","first-page":"1035A","DOI":"10.1182\/blood.V110.11.3536.3536","article-title":"The KIT tyrosine kinase inhibitor midostaurine (PKC412) exhibits a high response rate in aggressive systemic mastocytosis (ASM): interim results of a Phase II trial","volume":"110","author":"Gotlib J","year":"2007","journal-title":"Blood"},{"key":"e_1_2_6_31_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0609.2008.01048.x"},{"key":"e_1_2_6_32_2","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-08-0366"},{"key":"e_1_2_6_33_2","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1182\/blood.V110.11.1541.1541","article-title":"Delineation of a KIT\u2010independent oncogenic pathway in neoplastic mast cells that involves Lyn and Btk, and can be disrupted by the KIT\/Lyn\/Btk\u2010targeting drug dasatinib","volume":"110","author":"Gleixner KV","year":"2007","journal-title":"Blood"}],"container-title":["European Journal of Clinical Investigation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1365-2362.2008.02036.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1365-2362.2008.02036.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,13]],"date-time":"2023-10-13T17:54:35Z","timestamp":1697219675000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1365-2362.2008.02036.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,10,21]]},"references-count":32,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2008,11]]}},"alternative-id":["10.1111\/j.1365-2362.2008.02036.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1365-2362.2008.02036.x","archive":["Portico"],"relation":{},"ISSN":["0014-2972","1365-2362"],"issn-type":[{"value":"0014-2972","type":"print"},{"value":"1365-2362","type":"electronic"}],"subject":[],"published":{"date-parts":[[2008,10,21]]}}}